Immunoediting and Persistence of Antigen-specific Immunity in Patients Who Have Previously Been Vaccinated with NY-ESO-1 Protein Formulated in ISCOMATRIX™

Overview

Journal Cancer Immunol Immunother

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2011 Jun 24

PMID 21698545

Citations 20

Authors

Theo Nicholaou

Weisan Chen

Ian D Davis

Heather M Jackson

Nektaria Dimopoulos

Catherine Barrow

Judy Browning

Duncan MacGregor

David Williams

Wendie Hopkins

Eugene Maraskovsky

Ralph Venhaus

Linda Pan

Eric W Hoffman

Lloyd J Old

Jonathan Cebon

Affiliations

Soon will be listed here.

Abstract

Background: NY-ESO-1 protein formulated in ISCOMATRIX™ results in CD4+, CD8+ T cell and antibody-mediated immunity. We evaluated persistence of immunity, relapse-free survival and tumour antigen expression upon relapse in patients vaccinated in an earlier trial.

Methods: Immunity was measured in 28 patients with resected NY-ESO-1-expressing tumours (melanoma 25, breast 3) 252-1,155 days (median = 681) after vaccination. In the earlier vaccination, trial patients received NY-ESO-1 with ISCOMATRIX™ adjuvant at three protein doses 10 μg, 30 μg or 100 μg (n = 14); 100 μg NY-ESO-1 protein (n = 8) or placebo (n = 6), together with 1 μg of intradermal (ID) NY-ESO-1 protein twice for DTH skin testing. Immune responses assessed in the current study included antibody titres, circulating NY-ESO-1-specific T cells and DTH reactivity 2 days after DTH skin testing with NY-ESO-1 protein (1 μg) or peptides (10 μg). Relapse-free survival was determined for 42 melanoma patients. On relapse NY-ESO-1 and HLA, class I was assessed by immunohistochemistry in 17.

Results: Persisting anti-NY-ESO-1 immunity was detected in 10/14 recipients who had previously received vaccine with ISCOMATRIX™ adjuvant. In contrast, immunity only persisted in 3/14 who received 100 μg un-adjuvanted NY-ESO-1 protein (3/8) or 2 μg DTH protein (0/6) P = 0.02. Hence, persisting NY-ESO-1 immunity was associated with prior adjuvant. Tumour NY-ESO-1 or HLA class I was downregulated in participants who relapsed suggesting immunoediting had occurred.

Conclusion: Immunoediting suggests that a signal of anti-tumour activity was observed in high-risk resected melanoma patients vaccinated with NY-ESO-1/ISCOMATRIX™. This was associated with measurable persisting immunity in the majority of vaccinated subjects tested. A prospective randomised trial has been undertaken to confirm these results.

Citing Articles

Immunotherapy resistance driven by loss of NY-ESO-1 expression in response to transgenic adoptive cellular therapy with PD-1 blockade.

Frankiw L, Singh A, Peters C, Comin-Anduix B, Berent-Maoz B, Macabali M J Immunother Cancer. 2023; 11(5).

PMID: 37156551 PMC: 10173990. DOI: 10.1136/jitc-2023-006930.

Targeted Cancer Immunotherapy: Nanoformulation Engineering and Clinical Translation.

Yu M, Yang W, Yue W, Chen Y Adv Sci (Weinh). 2022; 9(35):e2204335.

PMID: 36257824 PMC: 9762307. DOI: 10.1002/advs.202204335.

Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma.

Cebon J, Gore M, Thompson J, Davis I, McArthur G, Walpole E J Immunother Cancer. 2020; 8(1).

PMID: 32317292 PMC: 7204806. DOI: 10.1136/jitc-2019-000410.

Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy.

Raza A, Merhi M, Inchakalody V, Krishnankutty R, Relecom A, Uddin S J Transl Med. 2020; 18(1):140.

PMID: 32220256 PMC: 7102435. DOI: 10.1186/s12967-020-02306-y.

Perspective: cancer vaccines in the era of immune checkpoint blockade.

Cebon J Mamm Genome. 2018; 29(11-12):703-713.

PMID: 30446791 PMC: 6267701. DOI: 10.1007/s00335-018-9786-z.

References

Gnjatic S, Atanackovic D, Jager E, Matsuo M, Selvakumar A, Altorki N . Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc Natl Acad Sci U S A. 2003; 100(15):8862-7. PMC: 166404. DOI: 10.1073/pnas.1133324100. View

Neumann F, Wagner C, Kubuschok B, Stevanovic S, Rammensee H, Pfreundschuh M . Identification of an antigenic peptide derived from the cancer-testis antigen NY-ESO-1 binding to a broad range of HLA-DR subtypes. Cancer Immunol Immunother. 2004; 53(7):589-99. PMC: 11034308. DOI: 10.1007/s00262-003-0492-6. View

Davis I, Chen W, Jackson H, Parente P, Shackleton M, Hopkins W . Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci U S A. 2004; 101(29):10697-702. PMC: 489997. DOI: 10.1073/pnas.0403572101. View

Schnurr M, Orban M, Robson N, Shin A, Braley H, Airey D . ISCOMATRIX adjuvant induces efficient cross-presentation of tumor antigen by dendritic cells via rapid cytosolic antigen delivery and processing via tripeptidyl peptidase II. J Immunol. 2009; 182(3):1253-9. DOI: 10.4049/jimmunol.182.3.1253. View

Nicholaou T, Ebert L, Davis I, Robson N, Klein O, Maraskovsky E . Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1. Immunol Cell Biol. 2006; 84(3):303-17. DOI: 10.1111/j.1440-1711.2006.01446.x. View

Chen Y, Scanlan M, Sahin U, Tureci O, Gure A, Tsang S . A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A. 1997; 94(5):1914-8. PMC: 20017. DOI: 10.1073/pnas.94.5.1914. View

Chen Q, Jackson H, Shackleton M, Parente P, Hopkins W, Sturrock S . Characterization of antigen-specific CD8+ T lymphocyte responses in skin and peripheral blood following intradermal peptide vaccination. Cancer Immun. 2005; 5:5. View

Barrow C, Browning J, MacGregor D, Davis I, Sturrock S, Jungbluth A . Tumor antigen expression in melanoma varies according to antigen and stage. Clin Cancer Res. 2006; 12(3 Pt 1):764-71. DOI: 10.1158/1078-0432.CCR-05-1544. View

Barr I, Mitchell G . ISCOMs (immunostimulating complexes): the first decade. Immunol Cell Biol. 1996; 74(1):8-25. DOI: 10.1038/icb.1996.2. View

10.

Shackleton M, Davis I, Hopkins W, Jackson H, Dimopoulos N, Tai T . The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun. 2004; 4:9. View

11.

Zeng G, Wang X, Robbins P, Rosenberg S, Wang R . CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proc Natl Acad Sci U S A. 2001; 98(7):3964-9. PMC: 31162. DOI: 10.1073/pnas.061507398. View

12.

Zarour H, Maillere B, Brusic V, Coval K, Williams E, Pouvelle-Moratille S . NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells. Cancer Res. 2002; 62(1):213-8. View

13.

Dunn G, Old L, Schreiber R . The three Es of cancer immunoediting. Annu Rev Immunol. 2004; 22:329-60. DOI: 10.1146/annurev.immunol.22.012703.104803. View

14.

Odunsi K, Qian F, Matsuzaki J, Mhawech-Fauceglia P, Andrews C, Hoffman E . Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci U S A. 2007; 104(31):12837-42. PMC: 1937553. DOI: 10.1073/pnas.0703342104. View

15.

Gnjatic S, Nishikawa H, Jungbluth A, Gure A, Ritter G, Jager E . NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res. 2006; 95:1-30. DOI: 10.1016/S0065-230X(06)95001-5. View

16.

Dannull J, Lesher D, Holzknecht R, Qi W, Hanna G, Seigler H . Immunoproteasome down-modulation enhances the ability of dendritic cells to stimulate antitumor immunity. Blood. 2007; 110(13):4341-50. DOI: 10.1182/blood-2007-04-083188. View

17.

Davis I, Chen Q, Morris L, Quirk J, Stanley M, Tavarnesi M . Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients. J Immunother. 2006; 29(5):499-511. DOI: 10.1097/01.cji.0000211299.29632.8c. View

18.

Robson N, McAlpine T, Knights A, Schnurr M, Shin A, Chen W . Processing and cross-presentation of individual HLA-A, -B, or -C epitopes from NY-ESO-1 or an HLA-A epitope for Melan-A differ according to the mode of antigen delivery. Blood. 2010; 116(2):218-25. DOI: 10.1182/blood-2009-10-249458. View

19.

Robbins P, Morgan R, Feldman S, Yang J, Sherry R, Dudley M . Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011; 29(7):917-24. PMC: 3068063. DOI: 10.1200/JCO.2010.32.2537. View

20.

Bender A, Karbach J, Neumann A, Jager D, Al-Batran S, Atmaca A . LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer. Cancer Immun. 2007; 7:16. PMC: 2935748. View